{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:24:00Z","timestamp":1782631440381,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020707","name":"Janssen Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Advanced\/metastatic urothelial cancer (a\/m UC) still has a poor prognosis despite the recent medical advances. Recent studies demonstrated that fibroblast growth factor receptor (<jats:italic>FGFR<\/jats:italic>) gene alterations (GAs) may be driver genes for UC; however, the proportion of UC genetic panel testing in Japan remains low. We clarified the proportion of patients with <jats:italic>FGFR2\/3<\/jats:italic> GAs, treatment patterns, and clinical outcomes in a\/m UC patients in Japan. This study was a descriptive epidemiological study using the MONSTAR\u2010SCREEN database, and 138 patients with a\/m UC were evaluated. The primary endpoint was the proportion of patients with <jats:italic>FGFR2\/3<\/jats:italic> GAs. The secondary endpoints included treatment patterns, clinical outcomes, genomic status before and after treatment, etc. The proportion of <jats:italic>FGFR<\/jats:italic> GA\u2010positive patients in a\/m UC was 11.9%. The most common <jats:italic>FGFR<\/jats:italic> mutation variant and fusion gene were S249C (4.4%) and <jats:italic>FGFR3\u2010TACC3<\/jats:italic> fusion (3.7%), respectively. Fifty\u2010one patients were tested two or more times; a few changes were observed in the <jats:italic>FGFR<\/jats:italic> GA status, regardless of the treatment regimen. Co\u2010occurrence association was observed in <jats:italic>FGFR1<\/jats:italic> with <jats:italic>TET2<\/jats:italic>, and in <jats:italic>FGFR3<\/jats:italic> with <jats:italic>CHEK2<\/jats:italic> or <jats:italic>MLL2<\/jats:italic>. During the first\u2010, second\u2010, and third\u2010line treatment, median progression\u2010free survival (PFS) of GA\u2010positive patients was 7.3, 2.9, and 6.2\u2009months, while for GA\u2010negative patients, 6.9, 3.1, and 6.9\u2009months, respectively. This study revealed that one in eight a\/m UC patients had <jats:italic>FGFR2\/3<\/jats:italic> GAs, and a few changes were observed in <jats:italic>FGFR<\/jats:italic> GA status before and after treatment. Genetic testing will be beneficial for the selection of appropriate treatments after a diagnosis of a\/m UC.<\/jats:p>","DOI":"10.1111\/cas.70000","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T02:34:32Z","timestamp":1739327672000},"page":"1424-1432","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["<i>FGFR2\/3<\/i> Gene Alterations and Clinical Outcomes in Advanced\/Metastatic Urothelial Cancer in Japan: <scp>MONSTAR<\/scp>\u2010<scp>SCREEN<\/scp> Database Study"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"first","affiliation":[{"name":"Department of Medical Oncology National Cancer Center Hospital East  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-7958","authenticated-orcid":false,"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Renal and Genitourinary Surgery Hokkaido University Graduate School of Medicine  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashige","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Renal and Genitourinary Surgery Hokkaido University Graduate School of Medicine  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-4263","authenticated-orcid":false,"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[{"name":"Department of Urology Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"International Medical Center Saitama Medical University  Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Iwahori","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Murota","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Tatematsu","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7224-0541","authenticated-orcid":false,"given":"Yosuke","family":"Nakano","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-9930","authenticated-orcid":false,"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Urology Kyushu University Graduate School of Medical Sciences  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-6233","authenticated-orcid":false,"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[{"name":"Department of Urology Osaka University Graduate School of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0059"},{"key":"e_1_2_12_3_1","unstructured":"Cancer Information Service National Cancer Center Japan (National Cancer Registry Ministry of Health Labour and Welfare) \u201cCancer Statistics \u201d[Japanese] accessed August 6 2024 https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/21_bladder.html."},{"key":"e_1_2_12_4_1","unstructured":"Cancer Information Service National Cancer Center Japan \u201cCancer Survival in Hospital\u2010Based Cancer Registries \u201d[in Japanese] accessed August 6 2024 https:\/\/hbcr\u2010survival.ganjoho.jp."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.08.016"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy094"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4162"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5165"},{"key":"e_1_2_12_9_1","unstructured":"The Food and Drug Administration (FDA) \u201cFDA Approves Enfortumab Vedotin\u2010ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer \u201d2023accessed August 6 2024 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010enfortumab\u2010vedotin\u2010ejfv\u2010pembrolizumab\u2010locally\u2010advanced\u2010or\u2010metastatic\u2010urothelial\u2010cancer."},{"key":"e_1_2_12_10_1","unstructured":"The Food and Drug Administration (FDA) \u201cU.S. Food and Drug Administration Approves Opdivo\u00ae (Nivolumab) in Combination with Cisplatin and Gemcitabine for First\u2010Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma \u201d2024accessed August 6 2024. Bristol Myers Squibb."},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14281"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020\u20100334"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010021\u201001488\u20106"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10482"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20103212"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.02.028"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"e_1_2_12_19_1","unstructured":"National Cancer Center Center for Cancer Genomics and Advanced Therapeutics \u201cCenter for Cancer Genomics and Advanced Therapeutics Registration Status \u201d[Japanese] accessed August 6 2024 https:\/\/for\u2010patients.c\u2010cat.ncc.go.jp\/registration_status\/."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15132"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201021\u20103089"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2023.100003"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.008"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1935"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6112"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.039"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102530"},{"key":"e_1_2_12_29_1","unstructured":"Cancer and Disease Control Division Ministry of Health Labour and Welfare \u201cCancer Incidence of Japan 2019 \u201d[Japanese] accessed August 6 2024 https:\/\/www.mhlw.go.jp\/content\/10900000\/001231391.pdf."},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.003"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201015\u20100602"},{"key":"e_1_2_12_32_1","unstructured":"\u201cJapan's MHLW Approves PADCEV\u00ae (Enfortumab Vedotin) for Advanced Urothelial Cancer \u201daccessed November 21 2024 https:\/\/www.astellas.com\/en\/news\/17206."},{"key":"e_1_2_12_33_1","unstructured":"\u201cPD\u2010L1 Antibody Bavencio\u00ae (Generic Name: Avelumab (Genetical Recombination)) Approved for Additional Indication of Locally Advanced or Metastatic Urothelial Carcinoma \u201daccessed November 21 2024 https:\/\/www.merckgroup.com\/jp\u2010ja\/press\/merckbiopharma\/mbj\u2010news\/20210224.html."},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.030"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T13:12:21Z","timestamp":1746105141000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/cas.70000"],"URL":"https:\/\/doi.org\/10.1111\/cas.70000","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"2024-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}